


This Listing of Claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1. (currently amended): Substituted pyrazoline compounds of formula I,



wherein

R¹ represents hydrogen or a linear or branched C₁₋₄-alkyl group,

R², R³ and R⁴ independently of each other represent hydrogen, a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R⁸, SH, SR⁸, SOR⁸, SO₂R⁸, NH₂, NHR⁸, NR⁸R⁹, -(C=O)-NH₂, -(C=O)-NHR⁸ or -(C=O)-NR⁸R⁹ whereby R⁸ and R⁹ for each substituent independently represent linear or branched C₁₋₆ alkyl,

R⁵ and R⁶ independently of each other represent a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R¹⁰, SH, SR¹⁰, SOR¹⁰, NH₂, NHR¹⁰, NR¹⁰R¹¹, -(C=O)-NH₂, -(C=O)-NHR¹⁰ or -(C=O)-NR¹⁰R¹¹, whereby R¹⁰ and optionally R¹¹ for each substituent independently represent linear or branched C₁₋₆ alkyl;

R⁷ represents hydrogen, a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R¹⁰, SH, SR¹⁰, SOR¹⁰, NH₂, NHR¹⁰, NR¹⁰R¹¹, -(C=O)-NH₂, -(C=O)-NHR¹⁰ or -(C=O)-NR¹⁰R¹¹, whereby R¹⁰ and optionally

R¹¹ for each substituent independently represent linear or branched C₁₋₆ alkyl;


with the proviso that

if R¹ and R⁷ are H and R⁵ and R⁶ both represent Cl in the 3- and 4-position of the phenyl ring
neither of R², R³ and R⁴ may represent F in the 4-position of the phenyl ring if the other two of
R², R³ and R⁴ both represent H;

optionally in a form of one of its stereoisomers or a racemate or in a form of a mixture of at least
two of its stereoisomers, in any mixing ratio, or a corresponding N-oxide thereof, or a
physiologically acceptable salt thereof.

2. (original): Compounds according to claim 1, characterized in that at least one of R², R³ or R⁴
represents hydrogen, while at least one of R², R³ or R⁴ is different from hydrogen.
3. (previously presented): Compounds according to claim 1, characterized in that R⁷ represents
hydrogen.
4. (previously presented): Compounds according to claim 1, characterized in that R², R³ and R⁴
independently of each other represent hydrogen, a linear or branched C₁₋₆-alkyl group, a halogen
atom, or CF₃.
5. (currently amended): Compounds according to claim 1, characterized in that R⁵ and R⁶
independently of each other represent ~~a linear or branched C₁₋₆-alkyl group~~, a halogen atom, or
CF₃.
6. (previously presented): Compounds according to claim 1, characterized in that R² represents a
chlorine atom in the 4-position of the phenyl ring, while R³ and R⁴ represent hydrogen.

7. (previously presented): Compounds according to claim 1, characterized in that R⁵ and R⁶ each represent chlorine atoms in the 2- and 4-position of the phenyl ring, while R⁷ represents hydrogen.
8. (previously presented): Compounds according to claim 1, characterized in that R¹ represents hydrogen, methyl or ethyl.
9. (currently amended): Compounds of formula II according to claim 1



II

wherein

R¹ represents hydrogen or a linear or branched C₁₋₄-alkyl group,

R¹² or R¹³ independently of each other represent a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, SH, NH₂, hydrogen, methyl, ethyl, F, Cl, Br or CF₃,


R¹⁴ or R¹⁵ independently of each other represent a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, SH, NH₂, methyl, ethyl, F, Cl, Br or CF₃,

optionally in a form of one of its stereoisomers or a racemate or in a form of a mixture of at least two of its stereoisomers, in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof.

10. (previously presented): Compounds according to claim 9 characterized in that R¹² and R¹³ independently of each other represent hydrogen, a linear or branched C₁₋₆-alkyl group, a halogen atom, or CF₃.
11. (currently amended): Compounds according to claim 9, characterized in that R¹⁴ and R¹⁵ independently of each other represent ~~a linear or branched C₁₋₆-alkyl group~~, a halogen atom, or CF₃.
12. (previously presented): Compounds according to claim 9, characterized in that R¹³ represents Cl and R¹² represents hydrogen.
13. (previously presented): Compounds according to claim 9, characterized in that R¹⁴ and R¹⁵ each represent Cl.
14. (previously presented): Compounds according to claim 9, characterized in that R¹ represents hydrogen, methyl or ethyl.
15. (previously presented): A compound according to claim 1 which is:
5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxylic acid,
optionally in the form of a corresponding N-oxide, a corresponding salt.


Claim 16-39 (canceled)

40. (previously presented): Process for the manufacture of substituted pyrazoline compounds of formula I or II, wherein R^1 is hydrogen, according to claim 1, characterized in that at least one benzaldehyde compound of formula III




(III)

wherein R^2 , R^3 and R^4 have the meaning according to claim 1, is reacted with a pyruvate compound of formula (IV)




(IV),

wherein G represents an OR group with R being a branched or unbranched C_{1-6} alkyl radical or G represents an O^-K group with K being a cation, to yield a compound of formula (V)




(V)

which is optionally isolated or optionally purified, and which is reacted with an optionally substituted phenyl hydrazine of formula (VI)



(VI)

or a corresponding salt thereof, wherein R^5 , R^6 and R^7 have the meaning according to claim 1, under inert atmosphere, to yield a compound of formula (VII)



(VII)

wherein R², R³, R⁴, R⁵, R⁶ and R⁷ have the meaning as given above, which is optionally isolated or optionally purified, and optionally esterified to an alkyl-ester if in the substituted pyrazoline compound of formula I according to claim 1 R¹ is a linear or branched C₁₋₄-alkyl group.

41. (currently amended): ~~Medicament~~ Composition comprising at least one substituted pyrazoline compound of formula I or II according to claim 1, and optionally one or more pharmaceutically acceptable excipients.

Claims 42-86 (canceled)